(19)
(11) EP 3 527 584 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.12.2020 Bulletin 2020/51

(45) Mention of the grant of the patent:
14.10.2020 Bulletin 2020/42

(21) Application number: 19152955.1

(22) Date of filing: 22.05.2013
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)

(54)

MEDICAL USE OF CELLS COMPRISING ANTI-NY-ESO-1 T CELL RECEPTORS

MEDIZINISCHE VERWENDUNG VON ZELLEN DIE ANTI-NY-ESO-1 T-ZELLREZEPTOREN BEINHALTEN

L'UTILISATION DES CELLULES QUI CONTIENENT DES RÉCEPTEURS DES LYMPHOCYTES T ANTI-NY-ESO-1 DANS LA MEDICINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 22.05.2012 US 201261650020 P

(43) Date of publication of application:
21.08.2019 Bulletin 2019/34

(60) Divisional application:
20201340.5

(62) Application number of the earlier application in accordance with Art. 76 EPC:
13726389.3 / 2852613

(73) Proprietor: The United States of America, as represented by the Secretary, Department of Health and Human Services
Bethesda, MD 20892-7660 (US)

(72) Inventors:
  • PARKHURST, Maria R.
    Ellicott City, MD 21043 (US)
  • MORGAN, Richard Arthur
    Center Harbor, NH 03226 (US)
  • ROSENBERG, Steven A.
    Potomac, MD 20854 (US)
  • ROSATI, Shannon Faith
    Richmond, VA 23224 (US)

(74) Representative: Grünecker Patent- und Rechtsanwälte PartG mbB 
Leopoldstraße 4
80802 München
80802 München (DE)


(56) References cited: : 
WO-A2-2009/042570
   
  • ROBBINS PAUL F ET AL: "Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 MAR 2011, vol. 29, no. 7, 1 March 2011 (2011-03-01), pages 917-924, XP002705979, ISSN: 1527-7755
  • JENNIFER A WARGO ET AL: "Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 58, no. 3, 2 August 2008 (2008-08-02) , pages 383-394, XP019706282, ISSN: 1432-0851
  • LEE L ET AL: "NY-ESO-1 MAY BE A POTENTIAL TARGET FOR LUNG CANCER IMMUNOTHERAPY", CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 5, no. 1, 1 January 1999 (1999-01-01) , pages 20-25, XP001015618, ISSN: 1081-4442
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).